Brian Nowosielski

AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.

Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.

Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.

This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.

In celebration of American Pharmacists Month, Melissa McGivney, PharmD, FAPhA, FCCP, provides a snapshot of where the profession has come and where it still has to go.

Sara Hover, RPh, FAARM, explains how these products are putting pharmacists at the center of safety and evidence evaluations one patient at a time.

During American Pharmacists Month, pharmacy teams reflect on their roles and explore ways to enhance patient care.

Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.

The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.

Melissa McGivney, PharmD, FAPhA, FCCP, helps celebrate American Pharmacists Month and the innovation driving the profession forward amongst US communities.

Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.

The novel tool can be used to inform vaccine policy, monitor impact, and essentially strengthen overall surveillance.

Melissa McGivney, PharmD, FAPhA, FCCP, discusses her career journey from her local pharmacy to a national leadership role with the American Pharmacists Association.

Researchers evaluate peer-reviewed literature on interventions to improve vaccine uptake among thousands of US adults studied between 2010 and 2015.

In celebration of the organization’s recent convention, NCPA released its annual digest report for members, providing a detailed overview of independent community pharmacy.

In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.

In part 2 of our pre-election series, detailing key health policies for pharmacists at this year’s midterms, a legal expert touches on MFN pricing, ACA subsidies, and more.

In this episode, our hosts examine the expanding role of incretin therapies in children and adolescents with obesity and type 2 diabetes.

GLP-1 adherence requires integrated care teams, administrative technology, and proactive clinical support to tackle complex challenges.

In part 1 of our midterm election FAQ series, AJ Barbarito, Esq, breaks down ongoing legal developments for pharmacists and what a change in Congressional control could mean for the profession.

Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.

First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.

With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.

EJ Stoepfel, RPh, MBA-HCA, discussed how community pharmacies can secure federal rural health funding to expand clinical services and integrate with care teams.

Rosalyn Otting, PharmD, BCGP, presents on how to close gaps between patients seeking better outcomes and pharmacies seeking recognition for their services.

Dorrit Trate, MHA, explored how community pharmacies can improve a multitude of patient experiences through pharma-sponsored support programming.

Researchers compared vaccine coadministration with single-dose, sequential vaccination for the RSVPreF3 OA vaccine formulation in adults.

Despite technology fostering a new generation of health care delivery, experts believe rural health solutions should be sought elsewhere.

Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.

Darren Mensch, PharmD, BCPS, BCACP, provides evidence-based nuance regarding the emergence of mRNA vaccine technology and health care’s understanding of it.